Creative Planning Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Creative Planning raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,881 shares of the medical equipment provider’s stock after purchasing an additional 5,842 shares during the period. Creative Planning’s holdings in Intuitive Surgical were worth $33,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Mirador Capital Partners LP raised its position in Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 50 shares during the period. Advisors Asset Management Inc. raised its holdings in shares of Intuitive Surgical by 18.1% in the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after buying an additional 1,129 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Intuitive Surgical by 617.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after acquiring an additional 76,649 shares during the last quarter. Brookstone Capital Management boosted its holdings in Intuitive Surgical by 22.4% during the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after acquiring an additional 2,289 shares during the period. Finally, M&G Plc grew its position in Intuitive Surgical by 53.5% in the 2nd quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after acquiring an additional 1,766 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $521.15 on Monday. The stock’s fifty day moving average price is $483.85 and its 200 day moving average price is $438.56. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $523.34. The company has a market cap of $184.85 billion, a price-to-earnings ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 earnings per share. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ISRG shares. Truist Financial boosted their target price on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Citigroup boosted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. BTIG Research set a $535.00 target price on Intuitive Surgical in a report on Friday. Finally, Stifel Nicolaus raised their price target on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $513.74.

Insiders Place Their Bets

In other news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the sale, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,120 shares of company stock valued at $25,528,753. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.